NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Demyelinating Disease


Return to Library

Free Demyelinating Disease Articles


Research findings from D.B. Bichuetti et al update understanding of multiple sclerosis



2009 JUN 15 - (NewsRx.com) -- According to recent research published in the journal Multiple Sclerosis, "Objectives To describe the clinical characteristics of patients with relapsing neuromyelitis optica (NMO) from a tertiary care center in Brazil and compare the groups with normal and abnormal brain magnetic resonance imaging (MRI). Retrospective review of 41 patients followed at the Neuroimmunology Clinic of the Federal University of Sao Paulo, Brazil, from 1994 to 2007."

" All patients had relapsing-remitting optic-spinal disease, long extending spinal cord lesions, and brain MRI not meeting Barkhof criteria for multiple sclerosis (MS), thus fulfilling the 1999 and 2006 Wingerchuck criteria for NMO. Mean follow-up time was 52 months; mean age of onset was 32.6 years. The mean relapse rate (RR) and progression index (PI) were 1.0 and 0.9, respectively. Twenty-four patients had brain lesions not compatible with MS on MRI, and there were no statistical differences on PI and RR between patients who had brain lesions and patients who did not. Incomplete recovery, but not the type of first relapse, correlated with a worse prognosis. Seventeen patients were tested for NMO-IgG (anti-aquaporin-4 antibody) with 41% positivity. In this series, we did not find a statistical difference of disease progression between patients with and without brain lesions, suggesting that the presence of brain abnormalities is not a marker of disease severity," wrote D.B. Bichuetti and colleagues.

The researchers concluded: "Multiple Sclerosis 2009; 15: 613-619. http://msj.sagepub.com'."

Bichuetti and colleagues published their study in Multiple Sclerosis (Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Multiple Sclerosis, 2009;15(5):613-619).

For additional information, contact D.B. Bichuetti, Rua Pedro de Toledo 377, BR-04039000 Sao Paulo, Brazil.

The publisher's contact information for the journal Multiple Sclerosis is: Sage Publications Ltd., 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England.

Keywords: Brazil, Sao Paulo, Demyelinating Disease, Epidemiology, Immunology, Magnetic Resonance, Multiple Sclerosis, Neuroimmunology, Neurology, Neuromyelitis, Neuromyelitis Optica, Spinal Disease.

This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2009, Pain & Central Nervous System Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login